Microglia/macrophages (MMΦ) are highly plastic phagocytes that can promote both injury and repair in diseased brain through the distinct function of classically activated and alternatively activated subsets. The role of MMΦ polarization in intracerebral hemorrhage (ICH) is unknown. Herein, we comprehensively characterized MMΦ dynamics after ICH in mice and evaluated the relevance of MMΦ polarity to hematoma resolution. MMΦ accumulated within the hematoma territory until at least 14 days after ICH induction. Microglia rapidly reacted to the hemorrhagic insult as early as 1-1.5 h after ICH and specifically presented a "protective" alternatively activated phenotype. Substantial numbers of activated microglia and newly recruited monocytes also assumed an early alternatively activated phenotype, but the phenotype gradually shifted to a mixed spectrum over time. Ultimately, markers of MMΦ classic activation dominated at the chronic stage of ICH. We enhanced MMΦ alternative activation by administering intraperitoneal injections of rosiglitazone, and subsequently observed elevations in CD206 expression on brain-isolated CD11b + cells and increases in IL-10 levels in serum and perihematomal tissue. Enhancement of MMΦ alternative activation correlated with hematoma volume reduction and improvement in neurologic deficits. Intraventricular injection of alternative activation signature cytokine IL-10 accelerated hematoma resolution, whereas microglial phagocytic ability was abolished by IL-10 receptor neutralization. Our results suggest that MMΦ respond dynamically to brain hemorrhage by exhibiting diverse phenotypic changes at different stages of ICH. Alternative activation-skewed MMΦ aid in hematoma resolution, and IL-10 signaling might contribute to regulation of MMΦ phagocytosis and hematoma clearance in ICH.
Introduction
Intracerebral hemorrhage (ICH) accounts for the highest mortality among all strokes (van Asch et al., 2010) , and no therapeutic strategy has been approved for its treatment (Keep et al., 2012) . After an intraparenchymal bleed, primary injury develops within the first few hours as a result of hematoma formation, expansion, and the mass effect. Subsequently, secondary damage activates cytotoxic and inflammatory cascades (Wang, 2010; Zhou et al., 2014) that contribute substantially to neurologic deterioration in patients with ICH (Wu et al., 2010; Ziai, 2013) . Although preclinical studies have tried to identify potential neuroprotectants that target secondary injury (Kellner and Connolly, 2010), mortality and morbidity of ICH have not declined (Xi et al., 2014) . As targeting secondary injury does not appear to provide adequate intervention for ICH patients (Toyoda and Grotta, 2015) , an alternative strategy might be to remove the hematoma before it can release the toxic hemoglobin degradation products that elicit secondary injury cascades (Ni et al., 2016; Sonni et al., 2014) . Clinical evidence shows that hematoma size and expansion are the major determinants of ICH outcomes (Brott et al., 1997; LoPresti et al., 2014) . Until now, however, little preclinical work has evaluated potential strategies to limit hematoma expansion or accelerate hematoma resolution after ICH (Flores et al., 2016; King et al., 2011; Wu et al., 2016; Zhao et al., 2015b; Zhao et al., 2007b) .
Microglia/macrophages (MMΦ) are the major phagocytes in the innate immune system. Under in vitro conditions, MMΦ can be polarized into distinct classically and alternatively activated phenotypes; however, in response to microenvironmental signals in vivo, MMΦ dynamically switch their phenotype, both temporally during an immune response and based on the local stimuli (Hu et al., 2015; Mosser and Edwards, 2008) . Accumulating evidence indicates that classically activated and alternatively activated MMΦ within the lesion area can individually Neurobiology of Disease 103 (2017) [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] 
